CARsgen Therapeutics Holdings Limited (HKG:2171) shareholders should be happy to see the share price up 26% in the last month. But that is minimal compensation for the share price under-performance over the last year. After all, the share price is down 47% in the last year, significantly under-performing the market.
While the last year has been tough for CARsgen Therapeutics Holdings shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.
See our latest analysis for CARsgen Therapeutics Holdings
CARsgen Therapeutics Holdings isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
SEHK:2171 Earnings and Revenue Growth July 20th 2022
Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.
A Different Perspective
CARsgen Therapeutics Holdings shareholders are down 47% for the year, even worse than the market loss of 22%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. Putting aside the last twelve months, it's good to see the share price has rebounded by 24%, in the last ninety days. This could just be a bounce because the selling was too aggressive, but fingers crossed it's the start of a new trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 4 warning signs we've spotted with CARsgen Therapeutics Holdings .
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
卡斯根治疗控股有限公司(HKG:2171)股东应该很高兴看到股价在过去一个月上涨了26%。但这是对过去一年股价表现不佳的最低补偿。毕竟,该公司股价在过去一年下跌了47%,表现明显逊于大盘。
虽然过去的一年对CARsgen治疗控股公司的股东来说是艰难的一年,但过去的一周显示出了希望的迹象。因此,让我们看看较长期的基本面,看看它们是否是负回报的驱动因素。
查看我们对Carsgen Treateutics Holdings的最新分析
Carsgen治疗控股公司目前没有盈利,因此大多数分析师都会关注收入增长,以了解基础业务的增长速度。当一家公司没有盈利时,我们通常预计会看到良好的收入增长。这是因为,如果一家公司的收入增长微不足道,而且永远不会盈利,那么很难相信它会持续下去。
下图描述了收益和收入随时间的变化(通过单击图像来揭示确切的价值)。
联交所:2171盈利及收入增长2022年7月20日
资产负债表的强健至关重要。也许很值得一看我们的免费报告其财务状况如何随着时间的推移而发生变化。
不同的视角
Carsgen治疗控股公司的股东今年以来下跌了47%,甚至比22%的市场跌幅还要糟糕。这令人失望,但值得记住的是,整个市场的抛售不会有任何帮助。抛开过去12个月的情况不谈,很高兴看到股价在过去90天里反弹了24%。这可能只是一次反弹,因为抛售过于激进,但祈祷这是一种新趋势的开始。我发现,把股价作为衡量企业业绩的长期指标是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。为此,您应该意识到4个警示标志我们发现了卡斯根治疗控股公司。
如果你更愿意看看另一家公司--一家财务状况可能更好的公司--那么不要错过这一点免费已证明自己能够实现盈利增长的公司名单。
请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。